A Study on the Complications and Pathologic Results of the Patients Undergoing Magnetic Resonance Imaging Guided Prostate Biopsy
10.22465/kjuo.2018.16.2.63
- Author:
Byeongdo SONG
1
;
Sangchul LEE
Author Information
1. Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea. sclee@snubh.org
- Publication Type:Original Article
- Keywords:
Prostate;
Prostate biopsy;
Magnetic resonance imaging;
Complication;
Pathology
- MeSH:
Biopsy;
Classification;
Diffusion;
Dysuria;
Fever;
Gastrointestinal Hemorrhage;
Hematuria;
Hemorrhage;
Humans;
Magnetic Resonance Imaging;
Multivariate Analysis;
Pathology;
Prostate;
Prostatic Neoplasms;
Retrospective Studies;
Risk Factors;
Ultrasonography;
Urinary Retention
- From:Korean Journal of Urological Oncology
2018;16(2):63-68
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: We aimed to study clinicopathological parameters and complications of patients who underwent magnetic resonance imaging-transrectal ultrasonography fusion guided prostate biopsy (MRI-TRUS FGB). MATERIALS AND METHODS: We investigated 576 patients who underwent MRI-TRUS FGB of prostate from May 2003 to December 2017 retrospectively. The clinicopathological features and complications were presented, using the modified Clavien-Dindo classification system. RESULTS: Fourteen patients (2.4%) readmitted within 30 days after MRI-TRUS FGB due to complications, and 85.7% (12 of 14) of them complained mild to moderate complications, the Clavien-Dindo classification grades I and II. The most common complication was hematuria (n=5, 0.9%), followed by acute urinary retention (n=3, 0.5%), dysuria (n=2, 0.3%), fever (n=1, 0.2%), hematochezia (n=1, 0.2%). According to multivariate analysis, only age was the significant risk factor of overall complications and bleeding related complications. Two hundred thirteen patients were diagnosed as prostate cancer after MRI-TRUS FGB. When the Likert suspicious scale of prostate cancer on apparent diffusion coefficient (ADC) was ≤4, 27.8% (137 of 493) were diagnosed as prostate cancer, of whom 56.2% (77 of 137) were confirmed as prostate cancer only at randomized 12 cores. When the ADC suspicious level was grade 5, 91.6% (76 of 83) were diagnosed as prostate cancer, of whom 11.8% (7 of 76) were confirmed as prostate cancer only at randomized 12 cores. CONCLUSIONS: The present study demonstrates the safety of MRI-TRUS FGB in terms of complications. When ADC suspicious level is grade 5, MRI-TRUS FGB alone could be a reasonable measure to diagnose prostate cancer, but randomized 12-core prostate biopsy would be recommended additionally when ADC suspicious level is ≤4.
